There are 3163 resources available
971P - Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world study
Presenter: binghua dai
Session: Poster session 17
972P - Efficacy and safety of lenvatinib vs sorafenib in hepatocellular carcinoma: A multi-center real-world study from the LINK Research Network
Presenter: Jung Yong Hong
Session: Poster session 17
973P - Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 17
977P - Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: A multicenter cohort study
Presenter: Yi Chen
Session: Poster session 17
978P - Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, single center, phase Ⅱ clinical study
Presenter: Jinpeng Li
Session: Poster session 17
979P - Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial)
Presenter: Oliver Waidmann
Session: Poster session 17